FranklinJosephZieveMD
Internal Medicine • Richmond, VAAssociate Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine. Preventative Cardiology
Dr. Zieve is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1201 Broad Rock Blvd
Hunter Holmes Mcguire Va Medical Center
Richmond, VA 23249Phone+1 804-675-5151Fax+1 804-675-5139
Education & Training
University of MinnesotaResidency, Internal Medicine, 1974 - 1975- University of MinnesotaInternship, Internal Medicine, 1971 - 1972
- University of Minnesota Medical SchoolClass of 1971
Certifications & Licensure
VA State Medical License 1979 - 2026
MN State Medical License 1972 - 1983- American Board of Internal Medicine Internal Medicine
Clinical Trials
- VA NEPHRON-D: Diabetes iN Nephropathy Study Start of enrollment: 2008 Jul 01
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
Publications & Presentations
PubMed
- 12 citationsEfficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron
Journal of Clinical Lipidology. 2020-01-01 - 344 citationsEfficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron
Journal of Clinical Lipidology. 2015-11-01 - 17 citationsAtorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 yearsChristian Constance, Ori Ben-Yehuda, Nanette K. Wenger, Franklin J. Zieve, Jianxin Lin
Lipids in Health and Disease. 2014-01-13
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
